---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-023729"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T10:09:07.641496+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027

## Summary
- Purchase price: $85M enterprise value plus net China cash (~$75M) for total ~$160M.
- Transaction expected to close by mid-2025, subject to China regulatory approval.
- Proceeds will repay ~$80M term loan to Morgan Stanley Tactical Value; cash runway extended into 2027.
- Upon close, AstraZeneca gets full roxadustat rights in China; FibroGen retains U.S. and ex-AstraZeneca markets.
- Senior VP China Operations Christine Chung will depart upon closing; Phase 2 trial of FG-3246 in mCRPC expected 2Q 2025.

## SEC filing metadata
- accession: 0000950170-25-023729
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025023729/0000950170-25-023729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025023729/fgen-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-023729
- JSON: https://secwatch.observer/filing/0000950170-25-023729.json
- Plain text: https://secwatch.observer/filing/0000950170-25-023729.txt

## Key facts
- Executive change
  Christine L. Chung departed as Senior Vice President, China Operations at KYNTRA BIO, INC..
  - Action: cease employment
  - Role: Senior Vice President, China Operations
  source text: Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017025023729/0000950170-25-023729-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.